UNSPSC 51384616: Pirazolac

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C17H12ClFN2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FWY2578LP5, chemically known as 1h-pyrazole-3-acetic acid, 4-(4-chlorophenyl)-1-(4-fluorophenyl)- but generally known as pirazolac, which bears US NIH Compound Identifier 51222. European Medicines Agency schedules Pirazolac in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09898MIG.

UNSPSC 51384616 Pirazolac is a Commodity code that encompasses pharmaceutical products and related health-system supplies procured by state and local health agencies, though recent activity in this specific code shows limited direct solicitation. State and local governments use this code tier to purchase specific pharmaceutical compounds and related medical supplies, typically through competitive bidding or cooperative purchasing frameworks. Issuing bodies include county health departments, state health and human services agencies, and multistate cooperative purchasing alliances that aggregate demand across multiple jurisdictions. The recent opportunities tagged to this code span naloxone procurement by county health systems, direct-to-manufacturer prescription initiatives by state pharmacy benefit programs, and generic pharmaceutical contracts through multistate cooperative agreements—reflecting a mix of emergency-response supplies, ongoing pharmacy benefit management, and bulk pharmaceutical sourcing.

Recent activity centers in Florida, Texas, and Minnesota. Seminole County, Florida posted an IFB (IFB60459723LAS) on June 30, 2026, with a due date of July 26, 2023, for annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems with quarterly deliveries; the Texas Health and Human Services Commission issued an RFI (HHS0017013) on April 3, 2026, to explore direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP (S1070000015802) posted January 20, 2026, with a response deadline of March 26, 2026, for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities including Oregon, requiring vendors to supply through three authorized wholesalers and maintain cGMP and Drug Supply Chain Security Act compliance.